Global medical companies are launching hundreds of state-of-the-art technologies in the medical product pavilion of the ongoing China International Import Expo.

Siemens Healthineers displays nearly 20 cutting-edge technology products and a wide array of solutions, including 10 new offerings launched and exhibited for the first time.

Blockbuster exhibits include two unique research-focused MRI systems: Magnetom Terra.X, a 7T ultra-high-field MRI, and Magnetom Cima.X, a 200/200 ultra-high-gradient MRI as the first dual ultra-high research platform, which the company said will help researchers identify new imaging biomarkers for diseases in the fields of oncology, neurology, and cardiology.

France's largest healthcare company Sanofi held a ceremony to open its booth on Wednesday. Its exhibition features the company's global R&D pipeline, including 12 potential blockbuster products, and seven transformative therapies in the field of immunology.

Dupixent, a highlighted exhibit, is showcased for the indication of chronic obstructive pulmonary disease for the first time at the CIIE. As the world's first approved targeted medicine to treat COPD, its approval in China in September came earlier than that in the United States. Also, China took less time in making this approval compared with the European Union and the US, setting a new record of introducing innovative medicines to benefit Chinese patients.

Novartis showcases multiple innovative products for the treatment of cardiovascular and renal diseases. For the first time, the innovative drugs Atrasentan and Fabhalta for the treatment of IgA nephropathy make a joint appearance at the CIIE.

Atrasentan is the first non-immunological, highly selective precision therapeutic drug for IgAN that has been submitted for marketing approval in China. Fabhalta is the world's first approved complement alternative pathway inhibitor for the reduction of proteinuria in primary IgAN at risk of rapid progression. It is expected to take the lead in precision medicine in this disease field.

Abbott presents the world's first LCBP lung cancer risk assessment model suitable for the Chinese population. Its rapid assessment is a result combining CT imaging information, tumor marker combinations, and high-risk factors for lung cancer, such as the patient's age, gender, and smoking history.

This model can help reduce the proportion of patients with benign nodules undergoing invasive examination or surgical treatment, and accelerate early diagnosis of patients with malignant pulmonary nodules.

The kidney care business of Baxter will be spun off and formed as a separate company Vantive, which was unveiled during the CIIE on Wednesday. Senior executives of the future company from global to China level attended the brand unveiling ceremony.

"We feel honored to introduce the new brand of Vantive at the 7th CIIE, and share our brand strategy of improving care experience for patients and medical teams around the world, including those in China," said Chris Toth, executive vice-president and group president of kidney care business at Baxter, and future CEO of Vantive.

"Also, CIIE provides us with an opportunity to communicate with the government, clinical healthcare professionals, and partners, so that we can improve the accessibility of high-quality medical resources through the joint efforts of all parties," he said.

A number of leading products and treatment solutions in the areas of peritoneal dialysis, hemodialysis, and acute and critical treatment are showcased at Vantive's booth at the CIIE.